Literature DB >> 11173651

Role of Complement and Antibodies in the Control and Facilitation of HIV Disease.

Zoltán Prohászka1, Ferenc D Tóth, Dénes Bánhegyi, George Füst.   

Abstract

In humans the HIV infection results in a chronic disease with a permanent fight between factors controlling HIV and the escape of the virus. Fromthese control mechanisms the present review summarizes the role betwen complement and autoantibodies; the competition of complement and anti-HIV antibodies for binding sites, the role of mannan-binding lectin in the susceptibility to and in the survival after HIV infection, the contribution of complement-dependent enhancing type antibodies to the clinical progression of HIV disease as well as the changing pattern of some autoantibodies (mimicking MHC class II molecules, anti-heat shock protein 60 antibodies and anti-C1q antibodies) which were found to correlate to immunological and clinical parameters.

Entities:  

Year:  1997        PMID: 11173651     DOI: 10.1007/bf02904290

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  46 in total

1.  Complement activation decreases the ability of HIV transmembrane envelope protein to bind to specific antibody.

Authors:  F el Jarrah; T Hidvégi; E Ujhelyi; G Gyapay; V Salavecz; J J Origer; S Hollán; G Füst
Journal:  AIDS       Date:  1992-09       Impact factor: 4.177

Review 2.  Mannan-binding protein, a complement activating animal lectin.

Authors:  S Thiel
Journal:  Immunopharmacology       Date:  1992 Sep-Oct

3.  Complete nucleotide sequence of the AIDS virus, HTLV-III.

Authors:  L Ratner; W Haseltine; R Patarca; K J Livak; B Starcich; S F Josephs; E R Doran; J A Rafalski; E A Whitehorn; K Baumeister
Journal:  Nature       Date:  1985 Jan 24-30       Impact factor: 49.962

4.  Further characterization of the interaction between the C1q subcomponent of human C1 and the transmembrane envelope glycoprotein gp41 of HIV-1.

Authors:  N M Thielens; I M Bally; C F Ebenbichler; M P Dierich; G J Arlaud
Journal:  J Immunol       Date:  1993-12-01       Impact factor: 5.422

5.  Neutralizing and complement-dependent enhancing antibodies in different stages of HIV infection.

Authors:  F D Tóth; B Szabó; E Ujhelyi; K Pálóczi; A Horváth; G Füst; J Kiss; D Bánhegyi; S R Hollán
Journal:  AIDS       Date:  1991-03       Impact factor: 4.177

6.  Circulating levels of mannose binding protein in human immunodeficiency virus infection.

Authors:  G Senaldi; E T Davies; M Mahalingam; J Lu; A Pozniak; M Peakman; K B Reid; D Vergani
Journal:  J Infect       Date:  1995-09       Impact factor: 6.072

7.  An Hsp60 related protein is associated with purified HIV and SIV.

Authors:  S R Bartz; C D Pauza; J Ivanyi; S Jindal; W J Welch; M Malkovsky
Journal:  J Med Primatol       Date:  1994 Feb-May       Impact factor: 0.667

8.  The envelope glycoprotein of HIV-1 gp120 and human complement protein C1q bind to the same peptides derived from three different regions of gp41, the transmembrane glycoprotein of HIV-1, and share antigenic homology.

Authors:  H Stoiber; N M Thielens; C Ebenbichler; G J Arlaud; M P Dierich
Journal:  Eur J Immunol       Date:  1994-02       Impact factor: 5.532

9.  Comparative study of antibodies that are associated with disease progression in HIV disease.

Authors:  F D Tóth; C Süsal; E Ujhelyi; D Bánhegyi; J Kiss; V Daniel; I Nagy; G Opelz; G Füst
Journal:  Immunol Lett       Date:  1994-06       Impact factor: 3.685

10.  A human serum mannose-binding protein inhibits in vitro infection by the human immunodeficiency virus.

Authors:  R A Ezekowitz; M Kuhlman; J E Groopman; R A Byrn
Journal:  J Exp Med       Date:  1989-01-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.